Enhanced cytotoxic activity of BRAF, MEK and PI3K inhibition with combination CDK4/6 inhibition in melanoma cells

被引：0
|
作者：
Zhang, Yanping [1 ]
Peng, Guangyong [1 ]
Hsueh, Eddy C. [1 ]
机构：
[1] St Louis Univ, St Louis, MO 63103 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2942
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2942
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
    H S Kim
    M Jung
    H N Kang
    H Kim
    C-W Park
    S-M Kim
    S J Shin
    S H Kim
    S G Kim
    E K Kim
    M R Yun
    Z Zheng
    K Y Chung
    J Greenbowe
    S M Ali
    T-M Kim
    B C Cho
    [J]. Oncogene, 2017, 36 : 3334 - 3345
  • [2] Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
    Kim, H. S.
    Jung, M.
    Kang, H. N.
    Kim, H.
    Park, C-W
    Kim, S-M
    Shin, S. J.
    Kim, S. H.
    Kim, S. G.
    Kim, E. K.
    Yun, M. R.
    Zheng, Z.
    Chung, K. Y.
    Greenbowe, J.
    Ali, S. M.
    Kim, T-M
    Cho, B. C.
    [J]. ONCOGENE, 2017, 36 (23) : 3334 - 3345
  • [3] Combination of MEK and PI3K inhibition in BRAF wild-type and mutant melanoma
    Zhang, Yanping
    Peng, Guangyong
    Hsueh, Eddy C.
    [J]. CANCER RESEARCH, 2016, 76
  • [4] CDK4 inhibition enhances anti-melanoma effects of BRAF/MEK inhibition
    Zhang, Yanping
    Hsueh, Eddy C.
    [J]. CANCER RESEARCH, 2017, 77
  • [5] Treatment of non-V600-mutated BRAF melanoma: A role for combination MEK and CDK4/6 inhibition
    Sosman, Jeffrey A.
    [J]. CANCER RESEARCH, 2015, 75
  • [6] Treatment of non-V600-mutated BRAF melanoma: A role for combination MEK and CDK4/6 inhibition.
    Sosman, Jeffrey A.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21
  • [7] CDK4/6 BLOCKADE IMPROVES THE EFFICACY OF PI3K INHIBITION IN BREAST CANCER
    不详
    [J]. CANCER DISCOVERY, 2014, 4 (09) : 983 - 983
  • [8] Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations
    Rittler, Dominika
    Molnar, Eszter
    Baranyi, Marcell
    Garay, Tamas
    Hegedus, Luca
    Aigner, Clemens
    Tovari, Jozsef
    Timar, Jozsef
    Hegedus, Balazs
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (20) : 1 - 18
  • [9] Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
    Lee, Cha Len
    Cremona, Mattia
    Farrelly, Angela
    Workman, Julie A.
    Kennedy, Sean
    Aslam, Razia
    Carr, Aoife
    Madden, Stephen
    O'Neill, Brian
    Hennessy, Bryan T.
    Toomey, Sinead
    [J]. CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [10] CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas
    Pita, Jaime M.
    Raspe, Eric
    Coulonval, Katia
    Decaussin-Petrucci, Myriam
    Tarabichi, Maxime
    Dom, Genevieve
    Libert, Frederick
    Craciun, Ligia
    Andry, Guy
    Wicquart, Laurence
    Leteurtre, Emmanuelle
    Tresallet, Christophe
    Marlow, Laura A.
    Copland, John A.
    Durante, Cosimo
    Maenhaut, Carine
    Cavaco, Branca M.
    Dumont, Jacques E.
    Costante, Giuseppe
    Roger, Pierre P.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2023, 14
12345